Patient P-02457
Synthetic patientMETA-24 · Day 116 · 45–54 · F · baseline S03Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Favorable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Favorable
Discontinuation risk
6%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S03
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- GI instability-15
- Inflammatory activity-12
- Treatment adherence+5
- Toxicity+4
- Nutritional resilience-2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable46 min
worsening · -6.1 vs previous 14 d
Sleep duration
Wearable7.9 h
worsening · -0.3 vs previous 14 d
Energy level
Daily log6.6/10
worsening · -0.6 vs previous 14 d
Steps
Wearable5,536
worsening · -502 vs previous 14 d
GI burden
Companion9.1/100
worsening · +13.8 vs previous 14 d
Adherence
Companion97.1 %
stable · +3.4 vs previous 14 d
Sleep quality
Wearable72.9/100
worsening · -9.2 vs previous 14 d
Glucose, CGM daily mean
CGM124 mg/dL
worsening · +5.9 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 84 from the failing basin, 27 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -6.8 next day on high-intake days · n 21
- More fatGI -4.4 next day on high-intake days · n 19
Would not help
- Nothing clearly counter-productive in the record.
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-6.8supporter · 95%
- Dietary fat load-4.4supporter · 73%
- Insoluble fibre-3.4supporter · 61%
- Caffeine-2.3no signal · 33%
- Histamine load-1.5no signal · 23%
- Simple carbohydrates-0.9no signal · 15%
- Alcohol+0.5no signal · 15%
- Ultra-processed food-0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
DNA
Fictional pharmacogenomic panel
- CYP2D6 Rapid metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 4.4 · butyrate capacity 67/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 52 ms
- Sleep
- 7.2 h
- Steps
- 5,600
- Resting HR
- 65 bpm
Daily log: GI score 9, nutritional resilience 67, adherence 97.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02031 | 40% | S12 | AD-05 | improved | 47 |
| P-02285 | 35% | S14 | AD-05 | no change | 39 |
| P-02555 | 32% | S01 | AD-05 | no change | 79 |
| P-02093 | 31% | S05 | AD-05 | no change | 40 |
| P-02267 | 40% | S09 | BR-03 | no change | 45 |
| P-02638 | 39% | S01 | BR-03 | improved | 41 |
| P-02280 | 38% | S07 | BR-03 | no change | 50 |
| P-02087 | 35% | S01 | BR-03 | no change | 40 |
| P-02586 | 38% | S18 | DT-01 | improved | 56 |
| P-02218 | 37% | S01 | DT-01 | improved | 61 |
| P-02235 | 37% | S14 | DT-01 | improved | 50 |
| P-02462 | 37% | S12 | DT-01 | improved | 65 |